|Dr. Frank H. Laukien Ph.D.||Chairman, CEO & Pres||2.44M||7.68M||1960|
|Mr. Gerald N. Herman||Exec. VP & CFO||1.08M||N/A||1958|
|Dr. Mark R. Munch Ph.D.||Corp. Exec. VP and Pres of Bruker Nano Group & Corp.||1.54M||1.27M||1962|
|Mr. Juergen Srega||Pres of Bruker CALID Group & Bruker Daltonics Division||960.8k||13.26M||1955|
|Dr. Falko Busse Ph.D.||Pres of Bruker BioSpin Group||738.54k||N/A||1968|
|Mr. Justin Joseph Ward||Sr. Director of Investor Relations & Corp. Devel.||N/A||N/A||N/A|
|Mr. J. Brent Alldredge J.D.||Gen. Counsel||N/A||N/A||1975|
|Mr. Collin J. D'Silva||Pres of Chemical Analysis Division||N/A||N/A||1957|
|Stacey Desrochers||Treasurer & Director of Investor Relations||N/A||N/A||N/A|
|Mr. Urban Faeh||Pres of Bruker Optics Division & Managing Director of Bruker Optik GmbH||N/A||N/A||N/A|
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Bruker Corporation’s ISS Governance QualityScore as of May 1, 2022 is 5. The pillar scores are Audit: 10; Board: 6; Shareholder Rights: 4; Compensation: 2.